ArticleCureus2025
An Atypical Case of Miller Fisher Syndrome: Classic Clinical Triad Despite Negative Anti-GQ1b Antibody.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miller Fisher syndrome (MFS), a variant of Guillain-Barré syndrome (GBS), was diagnosed in a 30-year-old patient following a mononucleosis infection. The progression of this patient's disease began with the classic triad of symptoms (areflexia, ophthalmoplegia, and ataxia) beginning at the head and progressing downward. Most notably, the diaphragm was spared. Ophthalmoplegia, ataxia, and areflexia were among the most defining of symptoms; however, this patient also presented with restlessness in his extremities and urinary hesitancy. Diagnostic workup of this patient included testing for anti-GQ1B antibodies in addition to a thorough history and physical exam. Initial treatment with intravenous immunoglobulin (IVIG) was unsuccessful. Plasmapheresis was ultimately initiated; however, the patient failed to complete treatment due to iatrogenic complications. The patient failed to return to follow-up appointments to determine recovery status. This case underscores the critical importance of a thorough and systematic diagnostic approach in managing atypical presentations of GBS variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.